Bozeman, MT, United States
Bozeman, MT, United States

Time filter

Source Type

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Italy Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. This report provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. The proton therapy market in Italy is anticipated to grow at a CAGR of around 25% during the period 2017 - 2022. In Italy, there are 3 proton beam therapy centers, which considerably boosts their capacity to treat a greater number of patients. The treatment of the first local patients with proton beams was administered in 2002 at Catania's INFN-LNS. Surging incidence rates of cancer patients in Italy, and technological advances are expected to give a boost to the domestic proton therapy marketplace. This report has been analyzed from 4 View Points: For more information about this report visit http://www.researchandmarkets.com/research/lrsdv2/italy_proton


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Poland Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. This report provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Proton Therapy is one of the most technologically advanced treatments for cancer. With an increasing incidence of cancer, there is a definite need for novel, cutting edge, treatment methods, such as, Proton Therapy. Unfortunately, the access to proton therapy is limited for a vast population, owing to a low number of proton therapy centers. There is currently only one operational proton therapy center in Poland. This report has been analyzed from 4 View Points: For more information about this report visit http://www.researchandmarkets.com/research/brvpcs/poland_proton


News Article | May 15, 2017
Site: www.businesswire.com

SAN FRANCISCO--(BUSINESS WIRE)--AMERICAN SHARED HOSPITAL SERVICES (NYSE MKT:AMS) (the "Company", "AMS"), a leading provider of turnkey technology solutions for advanced radiosurgical and radiation therapy services, today announced financial results for the first quarter of 2017. For the three months ended March 31, 2017, medical services revenue increased 16.0% to $4,914,000 compared to medical services revenue of $4,238,000 for the first quarter of 2016. First quarter revenue for the Company's initial proton therapy system installed at The Marjorie and Leonard Williams Center for Proton Therapy at UF Health Cancer Center-Orlando Health in Florida was $1,155,000. Revenue for the Company's Gamma Knife operations decreased to $3,619,000 for the first quarter of 2017 compared to $4,125,000 for the first quarter of 2016, primarily because two sites were offline during this year's first quarter for Cobalt-60 reload. Net income attributable to the Company for the first quarter of 2017 increased to $293,000, or $0.05 per share. This compares to net income attributable to the Company for the first quarter of 2016 of $51,000, or $0.01 per share. Medical services gross margin for the first quarter of 2017 increased to 47.7% of revenue, compared to medical services gross margin of 40.9% of revenue for the first quarter of 2016, primarily reflecting the increase in revenue from proton therapy. Operating income increased 51.1% to $754,000 for the first quarter of 2017 compared to operating income of $499,000 for the same period a year earlier. Income before income taxes increased 91.4% to $758,000 for the first quarter of 2017 compared to $396,000 for the first quarter of 2016. Non-GAAP pre-tax income, net of income attributable to non-controlling interest, was $509,000 for the first quarter of 2017. This compares to non-GAAP pre-tax income, net of income attributable to non-controlling interest, of $115,000 for the first quarter of 2016. Selling and administrative expenses for the first quarter of 2017 increased to $1,139,000, compared to selling and administrative expenses of $949,000 for the first quarter of 2016. Interest expense increased to $453,000 for the first quarter of 2017, compared to interest expense of $285,000 for the first quarter of 2016, primarily reflecting the addition of the proton center in Orlando. Adjusted EBITDA, a non-GAAP financial measure, was $2,616,000 for the first quarter of 2017, compared to $2,129,000 for the first quarter of 2016. Please refer to the financial statements included with this press release for a reconciliation of GAAP to this non-GAAP financial measure. At March 31, 2017, cash and cash equivalents was $2,403,000, compared to $2,871,000 at December 31, 2016. Shareholders' equity at March 31, 2017 was $27,774,000, or $4.87 per outstanding share. This compares to shareholders' equity at December 31, 2016 of $27,173,000, or $4.97 per outstanding share. Chairman and Chief Executive Officer Ernest A. Bates, M.D. said, "Patient treatments that began in April 2016 at our proton center at UF Health Cancer Center-Orlando Health continue to drive improved financial performance for AMS. Treatment volume at this center increased to 1,220 fractions in the first quarter, compared to 1,019 fractions performed in last year's fourth quarter, 869 fractions performed in the third quarter and 442 fractions performed in the second quarter. The reliability and throughput of the MEVION S250 proton system we supplied Orlando Health is meeting or exceeding our expectations, and we believe there is room for further growth in treatment volume. "The decrease in revenue in our Gamma Knife business in this year's first quarter was the anticipated consequence of routine Cobalt-60 reload at two of our centers. As previously announced, we will lose one of our sites due to the expiration of its contract term in this year's second quarter; however, we expect the Gamma Knife® Perfexion™ system we recently contracted to supply to Bryan Medical Center in Lincoln, Nebraska to begin treating patients in this year's second half. We also expect patient treatments to begin in this year's third quarter on a Gamma Knife located at the Air Force Hospital in Lima, Peru. "We are focused on taking advantage of the attractive growth opportunities available to us in both our proton and Gamma Knife businesses. Building on the success we have achieved to date, we are confident that AMS will deliver further growth in the years ahead." American Shared has scheduled a conference call at 12:00 p.m. PDT (3:00 p.m. EDT) today. To participate in the live call, dial (800) 588-4973 at least 5 minutes prior to the scheduled start time, and mention confirmation number 4493 2897. A simultaneous WebCast of the call may be accessed through the Company's website, www.ashs.com, or www.streetevents.com (institutional investors). A replay will be available for 14 days at these same internet addresses, or by dialing 888-843-7419 and entering 4493 2897# when prompted. American Shared Hospital Services provides turnkey technology solutions for advanced radiosurgical and radiation therapy services. AMS is the world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT and IMRT systems. AMS owns a common stock investment in Mevion Medical Systems, Inc., developer of the compact MEVION S250 Proton Therapy System. This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth in treatment volume of the MEVION S250 system, the expansion of the Company's proton therapy business, the growth of the Company, and the timing of treatments by new Gamma Knife systems) which involve risks and uncertainties including, but not limited to, the risks of variability of financial results between quarters, the risks of the Gamma Knife and radiation therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of investing in Mevion Medical Systems, Inc., and the risks of the timing, financing, and operations of the Company’s proton therapy business. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2016, and the definitive Proxy Statement for the Annual Meeting of Shareholders to be held on June 27, 2017. None of Adjusted EBITDA and non-GAAP pre-tax income, the non-GAAP measures presented in this press release and supplementary information, is a measure of performance under the accounting principles generally accepted in the United States ("GAAP"). These non-GAAP financial measures should not be considered as substitute for, and investors should also consider, income (loss) before income taxes, income from operations, net income attributable to the Company, earnings (loss) per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability. We use these non-GAAP financial measures as a means to evaluate period-to-period comparisons. Our management believes that these non-GAAP financial measures provide meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as the loss on early extinguishment of debt. We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Sweden Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. This report provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Proton Therapy is one of the most technologically advanced treatments for cancer. Unfortunately, the access to proton therapy is limited for a vast population, owing to a low number of proton therapy centers. There are only two operational proton therapy center in Sweden. With an increasing incidence of cancer, there is a definite need for novel, cutting edge, treatment methods, such as, Proton Therapy. This report has been analyzed from 4 View Points: For more information about this report visit http://www.researchandmarkets.com/research/m88j95/sweden_proton


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Germany Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. This report provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. Germany is the largest market for proton therapy in the European region. Currently, six proton therapy centers are operational in Germany. Still, industry experts believe that players will miss out on a majority of cancer patients who can benefit with proton therapy, overlooking a huge potential market. Germany represents a huge untapped market opportunity for proton therapy. The number of patients treated with proton therapy in Germany is very low whereas; the potential candidates for proton therapy are huge. This report has been analyzed from 4 View Points: For more information about this report visit http://www.researchandmarkets.com/research/cgkq4n/germany_proton


News Article | May 17, 2017
Site: www.enr.com

California Helena Chemical Co. is considering constructing a new fertilizer blending and storage facility at the Kings Industrial Park in Hanford. The project includes construction of building space, concrete storage domes, a spill containment system and equipment foundations; and purchase, relocation and installation of equipment for receiving and handling raw material, a truck scale, storage bins, liquid-storage tanks, pipe racks, and blending, filling, packaging, dust-suppression and loading equipment. The company will relocate and expand operations from its current location in Hanford. Helena Chemical Co., 7576 North Ingram Ave., Fresno, 93711. IR#CA170428. Iowa Kwik Trip, Inc. is planning to construct a biodiesel blending facility on a 4-acre site at the Martin Road Business Park in Waterloo. The project scope includes construction of a 6,000-sq-ft building with two or three bays and spill containment systems; fabrication and erection of four 35-ft-tall, double-walled, 30,000-gallon tanks; and purchase and installation of fuel-mixing equipment. Construction is expected to begin late in the third quarter or early in the fourth quarter of 2017. Kwik Trip, Inc., 1626 Oak St., La Crosse, Wis., 54602. IR#IA170408. Louisiana Provision Healthcare LLC is considering constructing the Louisiana Proton Therapy Center on the University Medical Center’s campus in New Orleans. The project scope includes design and construction of a 30,000-sq-ft building; installation of a cyclotron, a proton-beam line, gantries, electromagnets and scanning equipment; and purchase and installation of electrical-power feed and distribution equipment. Construction is expected to begin by the end of 2017. The estimated EPC cost is $100  million. Provision Healthcare LLC, 1400 Dowell Springs Blvd., Knoxville, Tenn., 37909. IR#LA170403. Maryland The Strouse Corporation is planning to construct an adhesive tape converting plant at the Westminster Technology Park in Westminster. The project scope includes construction of a 60,000-sq-ft building with clean-room manufacturing space; and purchase, relocation and installation of die cutting, packaging, assembly, spooling, printing and air-filtration equipment. Construction is expected to begin late in the second quarter of 2017. The Strouse Corp., 1130 Business Parkway South, Westminster, 21157. IR#MD170405. New Hampshire North Country Growers, a subsidiary of American Ag Energy, is planning to construct a vegetable greenhouse complex in Berlin. The project scope includes construction of two 10-acre greenhouse buildings; and purchase and installation of climate-control, water-recycling, irrigation and vegetable-cleaning equipment. The facility will have the capacity to produce 15 million heads of lettuce and 8 million lb of tomatoes per year. Construction is expected to begin in late May or June 2017. American Ag Energy, Inc., One Boston Place, Boston 02108. IR#NH170201. New Jersey Laboratorios Hipra, S.A., is planning to construct a veterinary pharmaceutical manufacturing, warehouse and U.S. headquarters facility on a 25-acre site at the South Jersey Technology Park at Rowan University’s West Campus in Mullica Hill. The project scope includes construction of a 375,000-sq-ft building; and purchase and installation of wet laboratory, formulation, filtration, air-handling, filling, packaging and conveying equipment. The estimated EPC cost is $100 million. Laboratorios Hipra, S.A., Av. De la Selva 135, 17170 Amer, Girona, Spain. IR#NJ170402. Information is derived from Industrial Reports (@IndustrialRpts), a market intelligence firm specializing in industrial construction. Access the full version of these reports for free as an ENR subscriber and see other recent projects by contacting ENRprojects@industrialreports.com.


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Nanoparticles - Metal & Metal Oxides Market In Healthcare By Type (Gold, Silver, Iron Oxide, Alumina, Gadolinium, Cerium), By Application (In-vivo Imaging, Targeted Drug Delivery, Proton Therapy, In-vitro assays), & Segment Forecasts, 2013 - 2025" report to their offering. The global nanoparticles - metal & metal oxides market in healthcare is anticipated to reach USD 80.74 billion by 2025 Several nanotechnologies based medicines have been put forward for approval by the FDA which is anticipated to propel growth. Success of nanomedicine has prompted the development of enhanced nanomaterials for clinical applications with particular emphasis in therapy and diagnostics. This has resulted into the significant production of metal oxide particles that hold potential utility in human medicine. Remarkable evolution has been made in nanoparticle based medicines for theranostic applications in disease management. Diverse metals have been used for development of medicines with a promise to optimize the efficacy of nanomedicines and to improve the current standard of medical and clinical practices. These particles are recognized to have major applications in drug delivery, diagnostic products, biomarker discovery, and product packaging. Widespread application spectrum of these particles in maintaining human health is expected to dramatically impact the progress of this market in the coming years. Moreover, metal oxides are observed to have significant role in cancer treatment. Nanoparticle-augmented systems enable high-concentration targeted drug delivery to cancer cells, which in turn, is expected to enhance the usage rate of metal nanoparticles for cancer treatment. Development of drug delivery strategies using nanoparticle approaches are expected to bring about changes effective for cancer treatment. For more information about this report visit http://www.researchandmarkets.com/research/zwf4c3/nanoparticles


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "France Proton Therapy Market (Actual & Potential), Patients Treated, List of Proton Therapy Centers and Forecast to 2022" report to their offering. This report provides a comprehensive assessment of the fast-evolving, high-growth Proton Therapy Market. France represents a huge untapped market opportunity for proton therapy. Proton therapy is an advanced treatment of tumors which minimizes the risks and increases the chances of the oncology patient, ensuring a better quality of life not only during but especially after the treatment. The main advantage of proton beams is the precise irradiation, most energy being given purely onto the tumour. In comparison with existing radiation methods, protons save the surrounding healthy tissue. With an increasing incidence of cancer, there is a definite need for novel, cutting edge, treatment methods, such as, Proton Therapy. Unfortunately, the access to proton therapy is limited for a vast population, owing to a low number of proton therapy centers. In France, currently only 2 proton therapy centers are operational. This report has been analyzed from 4 View Points: For more information about this report visit http://www.researchandmarkets.com/research/slqpg2/france_proton


Farace P.,Proton Therapy
Physics in Medicine and Biology | Year: 2014

A two-steps procedure is presented to convert dual-energy CT data to stopping power ratio (SPR), relative to water. In the first step the relative electron density (RED) is calculated from dual-energy CT-numbers by means of a bi-linear relationship: RED = a HUscH + b HUscL + c, where HUscH and HUscL are scaled units (HUsc = HU + 1000) acquired at high and low energy respectively, and the three parameters a, b and c has to be determined for each CT scanner. In the second step the RED values were converted into SPR by means of published poly-line functions, which are invariant as they do not depend on a specific CT scanner. The comparison with other methods provides encouraging results, with residual SPR error on human tissue within 1%. The distinctive features of the proposed method are its simplicity and the generality of the conversion functions. © 2014 Institute of Physics and Engineering in Medicine.


Patent
Proton Therapy | Date: 2013-03-27

Provided is a device for multi-portal irradiation of particle beams which makes it possible to carry out multi-portal irradiation by remote operation without an operator having to enter an irradiation room. This device for remotely multi-portal irradiation of particle beams includes an irradiation room and a control room. The irradiation room comprises an irradiation device for emitting a particle beam at an irradiation target, an irradiation control device for controlling the position and direction of the irradiation device, and a support stand for supporting the irradiation target. The control room, in turn, includes a control device and a remote operation controller. The control device controls the position and direction of the irradiation device by controlling the irradiation control device.

Loading Proton Therapy collaborators
Loading Proton Therapy collaborators